drugset
drugset / Trial / NCT06126380

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380 ↗

Phase 2 Enrolling by invitation 132 enrolled Eledon Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the long term safety and efficacy of AT-1501 (tegoprubart) compared with tacrolimus in patients undergoing kidney transplantation.

Timeline

Start
2023-10-25
Primary completion
2029-12
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tacrolimus Small molecule — Oral
Subject Tegoprubart Monoclonal antibody 20 mg/kg Intravenous

Indications

transplant rejection